Zoetis completes acquisition of Nexvet Biopharma

Zoetis Inc., manufacturer of veterinary vaccines and medicines for veterinarians, livestock producers, farmers, and pet owners, announced the completion of its $85 million acquisition of Nexvet Biopharma, a Tullamore, Ireland-based company that manufactures monoclonal antibodies (mAb) for companion animal pain management.

The annual market for chronic pain management therapies for companion animals is valued at $400 million annually, according to Zoetis, whose global headquarters for research and development are in Kalamazoo County, Mich.

Monoclonal antibodies, produced in a laboratory from a single clone of cells or a single cell line, have great potential in the field of pain-management for domestic animals, said Zoetis in a statement.

Nexvet comes with two pipeline products: ranevetmab, an mAb targeting nerve-growth factor, which is being investigated to treat chronic pain associated with osteoarthritis in dogs, and frunevetmab, which treats the same disease in cats.

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

___

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.